3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Colorectal Neoplasms
24
Pancreatic Neoplasms
21
Neoplasm Metastasis
16
Neuroblastoma
8
Rhabdomyosarcoma
6
Lung Neoplasms
6
Colonic Neoplasms
6
Rectal Neoplasms
5
Neoplasms
5
Esophageal Squamous Cell Carcinoma
5
Stomach Neoplasms
4
Small Cell Lung Carcinoma
4
Sarcoma, Ewing
4
Sarcoma
4
Esophageal Neoplasms
4
Adenocarcinoma Of Esophagus
4
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Biliary Tract Neoplasms
3
Wilms Tumor
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Kidney Neoplasms
2
Hereditary Sensory and Autonomic Neuropathies
2
Glioma
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Interventions
pasireotide
1
lutetium Lu 177 dotatate
1
lanreotide
1
amino-acid, glucose, and electrolyte solution
1
Sunitinib
1
Octreotide
1
Everolimus
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Irinotecan
×
90 days
×
Clear all
No trials found.